Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Yoshihiro Noguchi

Gifu Pharmaceutical University

Japan

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacology

100%

Pharmacotherapy

100%

Drug Safety

90%

Pharmacoepidemiology

50%

Adverse Effects

40%

Pharmacogenomic

40%

Drug Utilization

40%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles29

Comment on “Postmarketing adverse events of tamoxifen in male and female patients with breast cancer”

Article Link

Year:

2025

Comment on: ‘Drugs associated with epidermal necrolysis in children: A World Health Organization pharmacovigilance database analysis’

Article Link

Year:

2025

Caveats of Covariate Adjustment in Disproportionality Analysis for Best Practices

Article Link

Year:

2025

Comment on: "Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors used in Patients with Diabetes Mellitus and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database."

Article Link

Year:

2025

Impact of anxiety and chemotherapy side effects on quality of life in patients with malignant lymphoma.

Article Link

Year:

2025

Assessment of Cardiovascular Events Caused by New-Generation Androgen Receptor Pathway Inhibitors Used for Prostate Cancer: A Real-World Study in Japan

Article Link

Year:

2025

Detection Algorithms for Simple Two-Group Comparisons Using Spontaneous Reporting Systems

Article Link

Year:

2024

Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database

Article Link

Year:

2024

Effectiveness of distributing pocket cards in improving the behavior, attitude, and knowledge regarding proper medication use among junior high school students in Japan

Article Link

Year:

2024

Probable effects of polypharmacy and equivalent doses of psychotropic drugs on prevalence of adverse drug events among psychiatric inpatients in a general hospital in Japan

Article Link

Year:

2024

Association between CDK4/6 inhibitors and drug‐related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System

Article Link

Year:

2024

Are demographic findings really possible from reports in a spontaneous reporting system?

Article Link

Year:

2024

Association between duration of action of benzodiazepine hypnotic drugs and blepharospasm: A disproportionality analysis study using FDA Adverse Events Reporting System

Article Link

Year:

2024

Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database

Article Link

Year:

2023

Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study

Article Link

Year:

2023

Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database

Article Link

Year:

2023

Comment on: "Drug-associated kidney injury in children: a disproportionality analysis of the FDA adverse event reporting system"

Article Link

Year:

2023

Is it possible to identify risk factors for adverse drug reactions using a pharmacovigilance database based on spontaneous reporting?

Article Link

Year:

2023

Comment on: Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug–drug interactions

Article Link

Year:

2023

Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database

Article Link

Year:

2023

Tumor Lysis Syndrome with CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia: Signals from the FDA Adverse Event Reporting System

Article Link

Year:

2023

Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study

Article Link

Year:

2022

Comment on: "A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)"

Article Link

Year:

2022

Comment on: "A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)"

Article Link

Year:

2022

Effect of Dipeptidyl Peptidase-4 Inhibitors vs. Metformin on Major Cardiovascular Events Using Spontaneous Reporting System and Real-World Database Study

Article Link

Year:

2022

Effect of Dipeptidyl Peptidase-4 Inhibitors vs. Metformin on Major Cardiovascular Events Using Spontaneous Reporting System and Real-World Database Study

Article Link

Year:

2022

Comment on: "Drug–Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"

Article Link

Year:

2022

Comment on: "Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"

Article Link

Year:

2022

Do antibody-drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study

Article Link

Year:

2022

Collaborators2

Tomoaki Yoshimura

Gifu Pharmaceutical University

JAPAN

Tomoya Tachi

Professor

Nagoya University

JAPAN

How do I reach out?

Meet Kite AI

Yoshihiro Noguchi

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Articles29

Comment on “Postmarketing adverse events of tamoxifen in male and female patients with breast cancer”

Comment on: ‘Drugs associated with epidermal necrolysis in children: A World Health Organization pharmacovigilance database analysis’

Caveats of Covariate Adjustment in Disproportionality Analysis for Best Practices

Comment on: "Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors used in Patients with Diabetes Mellitus and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database."

Impact of anxiety and chemotherapy side effects on quality of life in patients with malignant lymphoma.

Assessment of Cardiovascular Events Caused by New-Generation Androgen Receptor Pathway Inhibitors Used for Prostate Cancer: A Real-World Study in Japan

Detection Algorithms for Simple Two-Group Comparisons Using Spontaneous Reporting Systems

Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database

Effectiveness of distributing pocket cards in improving the behavior, attitude, and knowledge regarding proper medication use among junior high school students in Japan

Probable effects of polypharmacy and equivalent doses of psychotropic drugs on prevalence of adverse drug events among psychiatric inpatients in a general hospital in Japan

Association between CDK4/6 inhibitors and drug‐related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System

Are demographic findings really possible from reports in a spontaneous reporting system?

Association between duration of action of benzodiazepine hypnotic drugs and blepharospasm: A disproportionality analysis study using FDA Adverse Events Reporting System

Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database

Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study

Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database

Comment on: &quot;Drug-associated kidney injury in children: a disproportionality analysis of the FDA adverse event reporting system&quot;

Is it possible to identify risk factors for adverse drug reactions using a pharmacovigilance database based on spontaneous reporting?

Comment on: Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug–drug interactions

Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database

Tumor Lysis Syndrome with CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia: Signals from the FDA Adverse Event Reporting System

Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study

Comment on: "A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)"

Comment on: "A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)"

Effect of Dipeptidyl Peptidase-4 Inhibitors vs. Metformin on Major Cardiovascular Events Using Spontaneous Reporting System and Real-World Database Study

Effect of Dipeptidyl Peptidase-4 Inhibitors vs. Metformin on Major Cardiovascular Events Using Spontaneous Reporting System and Real-World Database Study

Comment on: "Drug–Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"

Comment on: "Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"

Do antibody-drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study

Collaborators2

Tomoaki Yoshimura

Tomoya Tachi

How do I reach out?

Comment on: "Drug-associated kidney injury in children: a disproportionality analysis of the FDA adverse event reporting system"